Medicine and Dentistry
Infliximab
100%
Ulcerative Colitis
71%
Combination Therapy
57%
Surgery
42%
Patient
42%
Spontaneous Remission
28%
Morbidity
28%
Colectomy
28%
Randomized Controlled Trial
28%
Cost-Effectiveness Analysis
28%
Complication
14%
Diseases
14%
National Health Service
14%
Health Care Cost
14%
Preoperative Treatment
14%
Surgical Mortality
14%
Tumor Necrosis Factor
14%
Disease Course
14%
Infectious Complication
14%
Biological Therapy
14%
Symptom
14%
Enalapril Maleate
14%
Colon
14%
Therapeutic Procedure
14%
Healing
14%
Cancer
14%
Organ
14%
Pharmacology, Toxicology and Pharmaceutical Science
Infliximab
100%
Ulcerative Colitis
71%
Remission
28%
Morbidity
28%
Diseases
14%
Complication
14%
Inflammatory Bowel Disease
14%
Tumor Necrosis Factor
14%
Infectious Complication
14%
Disease Course
14%
Surgical Mortality
14%
Healing
14%
Symptom
14%
Enalapril Maleate
14%